The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
A nanobody modulates the p53 transcriptional program without perturbing its functional architecture
Abstract
The p53 transcription factor plays an important role in genome integrity. To perform this task, p53 regulates the transcription of genes promoting various cellular outcomes including cell cycle arrest, apoptosis or senescence. The precise regulation of this activity remains elusive as numerous mechanisms, e.g. posttranslational modifications of p53 and (non-)covalent p53 binding partners, influence the p53 transcriptional program. We developed a novel, non-invasive tool to manipulate endogenous p53. Nanobodies (Nb), raised against the DNA-binding domain of p53, allow us to distinctively target both wild type and mutant p53 with great specificity. Nb3 preferentially binds 'structural' mutant p53, i.e. R175H and R282W, while a second but distinct nanobody, Nb139, binds both mutant and wild type p53. The co-crystal structure of the p53 DNA-binding domain in complex with Nb139 (1.9 Å resolution) reveals that Nb139 binds opposite the DNA-binding surface. Furthermore, we demonstrate that Nb139 does not disturb the functional architecture of the p53 DNA-binding domain using conformation-specific p53 antibody immunoprecipitations, glutaraldehyde crosslinking assays and chromatin immunoprecipitation. Functionally, the binding of Nb139 to p53 allows us to perturb the transactivation of p53 target genes. We propose that reduced recruitment of transcriptional co-activators or modulation of selected post-transcriptional modifications account for these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two p53-binding nanobodies, Nb3 and Nb139, were obtained by immunization and panning procedures.527”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [527]
In the citing paper
“The cocrystal structure shows that the three complementary determining regions (CDRs) of Nb139 interact with p53-DBD by forming backbone or side chain hydrogen bonds and van der Waals forces (Fig. 12a).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [527]
In the citing paper
“Nb3 binds to the “structural mutations” R175H and R282W, and Nb139 binds to both wild-type and mutant p53, inhibiting the transcriptional capacity of p53.”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [527]
In the citing paper
“Nb3 binds to the “structural mutations” R175H and R282W, and Nb139 binds to both wild-type and mutant p53, inhibiting the transcriptional capacity of p53.”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [527]
In the citing paper
“Compared with the wild-type p53 structure, the Nb139/p53-DBD complex maintains the structural and DNA-binding properties of p53, which provides an innovative approach to study p53.527”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [527]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Transcriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · cited 1×
“To date more than 125 protein-coding genes have been documented to be direct transcriptional targets of p53 (5).”
BackgroundSmall-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“As small molecule drug design is supported by structural biology, the co-crystal structure of Nb3 in complex with the DBD could help identify the crucial binding site or help generate hypotheses for structure-based design for new p53 re-activating compounds (54).”
BackgroundRegulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy
Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999) · Science · doi:10.1126/science.285.5434.1733 · Cited by 1,270
Transcriptional Regulation by P53
Beckerman, R., & Prives, C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000935 · Cited by 569 · cited 2×
“Each of these features dynamically adds to the combinatorial regulation of the p53 response, and this magnitude of variables has made understanding the p53 transactivation requirements a formidable task (1,8).”
BackgroundDeconstructing p53 transcriptional networks in tumor suppression
Bieging, K. T., & Attardi, L. D. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.10.006 · Cited by 194 · cited 2×
“Each of these features dynamically adds to the combinatorial regulation of the p53 response, and this magnitude of variables has made understanding the p53 transactivation requirements a formidable task (1,8).”
BackgroundReactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA
Ditlev, S. B., Florea, R., Nielsen, M. A., Theander, T. G., Magez, S., Boeuf, P., & Salanti, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084981 · Cited by 31 · cited 1×
“oncology (10–13), parasitology (14,15), neuropathology (16) and immunology (17).”
Background
Research works printed but not linked: 54
- Vousden, 2002, Live or let die: the cell's response to p53, Nat. Rev. Cancer, 2, 594, 10.1038/nrc864 · DOI · Paper page
- Joerger, 2008, Structural biology of the tumor suppressor p53, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
- Hainaut, 1998, IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools, Nucleic Acids Res., 26, 205, 10.1093/nar/26.1.205 · DOI · Paper page
- Ho, 2003, Transcriptional repression mediated by the p53 tumour suppressor, Cell Death Differ., 10, 404, 10.1038/sj.cdd.4401191 · DOI · Paper page
- Mihara, 2003, p53 has a direct apoptogenic role at the mitochondria, Mol. Cell, 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
- De Clercq, 2013, L-plastin nanobodies perturb matrix degradation, podosome formation, stability and lifetime in THP-1 macrophages, PloS One, 8, e78108, 10.1371/journal.pone.0078108 · DOI
- Van Audenhove, 2014, Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization, FASEB J., 28, 1805, 10.1096/fj.13-242537 · DOI
- Pruszynski, 2013, Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody, Nucl. Med. Biol., 40, 52, 10.1016/j.nucmedbio.2012.08.008 · DOI
- Van Impe, 2013, A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis, Breast Cancer Res., 15, R116, 10.1186/bcr3585 · DOI
- Baral, 2006, Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor, Nat. Med., 12, 580, 10.1038/nm1395 · DOI · Paper page
- VanOverbeke, 2014, Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model, Mol. Ther., 22, 1768, 10.1038/mt.2014.132 · DOI
- De Clercq, 2013, Nanobody-induced perturbation of LFA-1/L-plastin phosphorylation impairs MTOC docking, immune synapse formation and T cell activation, Cell. Mol. Life Sci., 70, 909, 10.1007/s00018-012-1169-0 · DOI
- Van den Abbeele, 2010, A llama-derived gelsolin single-domain antibody blocks gelsolin-G-actin interaction, Cell. Mol. Life Sci., 67, 1519, 10.1007/s00018-010-0266-1 · DOI
- Bullock, 1997, Thermodynamic stability of wild-type and mutant p53 core domain, Proc. Natl Acad. Sci. U.S.A., 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
- Towbin, 1979, Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications, Proc. Natl Acad. Sci. U.S.A., 76, 4350, 10.1073/pnas.76.9.4350 · DOI · Paper page
- Xu, 2011, Gain of function of mutant p53 by coaggregation with multiple tumor suppressors, Nat. Chem. Biol., 7, 285, 10.1038/nchembio.546 · DOI · Paper page
- Pattyn, 2006, RTPrimerDB: the real-time PCR primer and probe database, major update 2006, Nucleic Acids Res., 34, D684, 10.1093/nar/gkj155 · DOI
- Hellemans, 2007, qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data, Genome Biol., 8, R19, 10.1186/gb-2007-8-2-r19 · DOI · Paper page
- McPherson, 1982, Preparation and Analysis of Protein Crystals
- Kabsch, 2010, Integration, scaling, space-group assignment and post-refinement, Acta Crystallogr. A, 66, 133
- Winn, 2011, Overview of the CCP4 suite and current developments, Acta Crystallogr. D, 67, 235, 10.1107/S0907444910045749 · DOI · Paper page
- McCoy, 2007, Phaser crystallographic software, J. Appl. Crystallogr., 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
- Langer, 2008, Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7, Nat. Protoc., 3, 1171, 10.1038/nprot.2008.91 · DOI · Paper page
- Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr. D, 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
- Afonine, 2012, Towards automated crystallographic structure refinement with phenix.refine, Acta Crystallogr. D, 68, 352, 10.1107/S0907444912001308 · DOI · Paper page
- Chen, 2010, MolProbity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. D, 66, 12, 10.1107/S0907444909042073 · DOI · Paper page
- Hubbard, 1991, Molecular recognition. Conformational analysis of limited proteolytic sites and serine proteinase protein inhibitors, J. Mol. Biol., 220, 507, 10.1016/0022-2836(91)90027-4 · DOI · Paper page
- McDonald, 1994, Satisfying hydrogen bonding potential in proteins, J. Mol. Biol., 238, 777, 10.1006/jmbi.1994.1334 · DOI · Paper page
- Lee, 2006, Chromatin immunoprecipitation and microarray-based analysis of protein location, Nat. Protoc., 1, 729, 10.1038/nprot.2006.98 · DOI · Paper page
- Gevry, 2007, p21 transcription is regulated by differential localization of histone H2A.Z, Genes Dev., 21, 1869, 10.1101/gad.1545707 · DOI · Paper page
- Collavin, 2010, p53-family proteins and their regulators: hubs and spokes in tumor suppression, Cell Death Differ., 17, 901, 10.1038/cdd.2010.35 · DOI · Paper page
- Rothbauer, 2008, A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins, Mol. Cell. Proteomics, 7, 282, 10.1074/mcp.M700342-MCP200 · DOI · Paper page
- Nooren, 2003, Diversity of protein-protein interactions, EMBO J., 22, 3486, 10.1093/emboj/cdg359 · DOI · Paper page
- Perkins, 2010, Transient protein-protein interactions: structural, functional, and network properties, Structure, 18, 1233, 10.1016/j.str.2010.08.007 · DOI · Paper page
- Wang, 2007, Structure of the human p53 core domain in the absence of DNA, Acta Crystallogr. D, 63, 276, 10.1107/S0907444906048499 · DOI
- Ory, 1994, Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation, EMBO J., 13, 3496, 10.1002/j.1460-2075.1994.tb06656.x · DOI · Paper page
- Chen, 2010, Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer, Structure, 18, 246, 10.1016/j.str.2009.11.011 · DOI · Paper page
- Lane, 1992, Cancer. p53, guardian of the genome, Nature, 358, 15, 10.1038/358015a0 · DOI · Paper page
- Vousden, 2009, Blinded by the light: the growing complexity of p53, Cell, 137, 413, 10.1016/j.cell.2009.04.037 · DOI · Paper page
- Lozano, 2010, Mouse models of p53 functions, Cold Spring Harb. Perspect. Biol., 2, a001115, 10.1101/cshperspect.a001115 · DOI
- Berglind, 2008, Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination, Cancer Biol. Ther., 7, 699, 10.4161/cbt.7.5.5712 · DOI
- Berns, 2004, A large-scale RNAi screen in human cells identifies new components of the p53 pathway, Nature, 428, 431, 10.1038/nature02371 · DOI · Paper page
- Vassilev, 2004, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
- Yu, 2012, Allele-specific p53 mutant reactivation, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
- Liu, 2013, Small molecule induced reactivation of mutant p53 in cancer cells, Nucleic Acids Res., 41, 6034, 10.1093/nar/gkt305 · DOI · Paper page
- Komarova, 2003, p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways, J. Biol. Chem., 278, 15465, 10.1074/jbc.C300011200 · DOI
- Rocha, 2003, The p53-inhibitor pifithrin-alpha inhibits firefly luciferase activity in vivo and in vitro, BMC Mol. Biol., 4, 9, 10.1186/1471-2199-4-9 · DOI
- Follis, 2014, The DNA-binding domain mediates both nuclear and cytosolic functions of p53, Nat. Struct. Mol. Biol., 21, 535, 10.1038/nsmb.2829 · DOI · Paper page
- Hagn, 2010, BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain, J. Biol. Chem., 285, 3439, 10.1074/jbc.M109.065391 · DOI
- Vaseva, 2009, The mitochondrial p53 pathway, Biochim. Biophys. Acta, 1787, 414, 10.1016/j.bbabio.2008.10.005 · DOI · Paper page
- Pardon, 2014, A general protocol for the generation of Nanobodies for structural biology, Nat. Protoc., 9, 674, 10.1038/nprot.2014.039 · DOI · Paper page
- Comel, 2014, The cytoplasmic side of p53's oncosuppressive activities, FEBS Lett., 588, 2600, 10.1016/j.febslet.2014.04.015 · DOI
- Delanote, 2010, An alpaca single-domain antibody blocks filopodia formation by obstructing L-plastin-mediated F-actin bundling, FASEB J., 24, 105, 10.1096/fj.09-134304 · DOI
- Oren, 2010, Mutant p53 gain-of-function in cancer, Cold Spring Harb. Perspect. Biol., 2, a001107, 10.1101/cshperspect.a001107 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
A chimeric viral platform for directed evolution in mammalian cells
Cole, A. J., Denes, C. E., Moreno, C. L., Hunault, L., Dobson, T., Hesselson, D., & Neely, G. G. (2025) · Nature Communications · doi:10.1038/s41467-025-59438-2 · Cited by 7
Metadata
- Authors
- Bethuyne, J., De Gieter, S., Zwaenepoel, O., Garcia-Pino, A., Durinck, K., Verhelle, A., Hassanzadeh-Ghassabeh, G., Speleman, F., Loris, R., & Gettemans, J.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-10-16
- Volume
- 42
- Issue
- 20
- Pages
- 12928-12938
- ISSN
- 1362-4962
- 0305-1048
- Cited by
- 44
- References
- 10
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.